title: Development of rheumatoid arthritis during the course of gefitinib therapy.
authors.forename: Gen
authors.initials: G
authors.lastname: Ohara
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Satoh
authors.forename: Mika
authors.initials: M
authors.lastname: Kohno
authors.forename: Daisuke
authors.initials: D
authors.lastname: Goto
authors.forename: Takayuki
authors.initials: T
authors.lastname: Sumida
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Hizawa
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy; D000970:Antineoplastic Agents / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000008:administration & dosage; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000209:etiology*; D004347:Drug Interactions; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage; D011799:Quinazolines / Q000009:adverse effects*; D012460:Sulfasalazine / Q000008:administration & dosage
chemical_list: D000970:Antineoplastic Agents; D018501:Antirheumatic Agents; D011799:Quinazolines; D012460:Sulfasalazine; D011239:Prednisolone; D000077156:Gefitinib